PCVX vs IONS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PCVX Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vaxcyte, Inc. Common Stock (PCVX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, PCVX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, PCVX sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PCVX | IONS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $10.2B | $4.7B | Larger Scale | PCVX |
| Trailing P/E Ratio Valuation | N/M | 90.9x | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | N/M | 90.9x | Lower Multiple | IONS |
| Revenue Growth (YoY) Growth | +0.0% | +54.9% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | 0.0% | -58.8% | Higher Margin | PCVX |
| Net Profit Margin Profitability | 0.0% | -56.9% | Higher Margin | PCVX |
| Return on Equity (ROE) Capital Efficiency | -42.7% | -108.0% | Higher ROE | PCVX |
| 52-Week Range Position Momentum | 41% ($42โ$91) | 2% ($27โ$87) | Stronger Trend | PCVX |
| Beta / 30D Volatility Risk Regime | 1.28ฮฒ ยท 57% Vol | 0.18ฮฒ ยท 86% Vol | Lower Realized Risk | PCVX |
| Unified Institutional Score Composite Signal | 47.3 / 100 (HOLD) | 63.9 / 100 (BUY) | Higher Composite | IONS |